Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gaboxadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gaboxadol SCHEMBL247815 | 0.98 | CHRM3 (0.46) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL5533785 | 0.98 | CHRM3 (0.46) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3983776 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3983708 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3981267 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3979055 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3980688 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL567225 | 0.96 | CHRM3 (0.49) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL1403323 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL1403469 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114072154-B | Gaboxadol and lithium compositions for treating psychotic disorders | 塞迪戈ABC有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-116267014-A | Cyclic deuterated gaboxadol and its use for treating psychotic disorders | CERTEGO治疗公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-114072154-A | Compositions of gaboxadol and lithium for treating psychotic disorders | CERTEGO治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220008388-A1 | COMBINATION OF GABOXADOL AND LITHIUM FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-01-13 | — | — | US | disclosed |
| EP-3883559-A1 | COMBINATION OF GABOXADOL AND LITHIUM FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008388-A1 | COMBINATION OF GABOXADOL AND LITHIUM FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRB3, GABRB2, SLC6A13 | CHRM3 2786/4885HTR2C 131/4885CHRM5 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.